Terms of the deal have not been disclosed, but Oracle said that it will add Relsys to its Health Sciences global business unit.
The database vendor claimed in a report that the combination of expertise will deliver the "only suite of software applications that supports end-to-end drug safety processes across clinical development, post-market surveillance and patient care".
"The health sciences industry is increasing investments in software that provides greater transparency into drug safety, and helps improve the overall safety of therapies," said Neil de Crescenzo, Oracle Health Sciences senior vice president and general manager.
"With the addition of Relsys, Oracle is uniquely positioned to help our customers improve drug safety by delivering a comprehensive software solution that enables our vision of integrated safety and risk management supported by advanced analytics."
J1043+2408 was observed for more than 10 years, and its radio light curve exhibited a periodic signal repeating in about 563 days
Success of Unity's test flight means Virgin Galactic is now close to taking its first paying tourist into space
V3 puts the pro-level football GPS tracker through its paces, and asks if it's more than a gimmick
Finding refutes many earlier studies that suggest that galaxies don't have much dark matter at the time of their birth